The present disclosure is directed to methods and formulations for treating, modifying, and/or managing at least one upper gastrointestinal symptom. Methods of using at least one .alpha.3 .beta.4 nAChR antagonist and formulations comprising at least one .alpha.3 .beta.4 nAChR antagonist, or pharmaceutically acceptable salt thereof are included.